N/A N=22 Asymmetric Subthalamic Deep Brain Stimulation for Axial Motor Dysfunction in Parkinson's Disease
Parkinson Disease
Primary: Change in Gait Velocity — 0.941; -0.069; -0.016 m/s — p=0.163
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=825 Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face
Acne Vulgaris
Primary: Mean Percent Change From Baseline in the Papules and Pustules Lesion Count — 68.18; 63.56; 50.72 percentage of lesion change
Phase 4 N=36 Eszopiclone in the Treatment of Insomnia and Fibromyalgia
Fibromyalgia · Insomnia
Primary: Change in Total Sleep Time (TST) as Recorded in Patient Diaries — 68.72; 13.47 minutes
N/A N=78 Visual and Refractive Outcomes of The ClarVista HARMONI™ Modular Intraocular Lens System (HMIOL)
Cataract · Aphakia
Primary: Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) by Visit - Cohort 1 — 30.2; 32.0; 32.0; 16.7 percentage of eyes
N/A N=571 What Matters Most: Choosing the Right Breast Cancer Surgery for You
Breast Cancer
Primary: Change in Decision Quality: Knowledge Subscale — 2.83; 2.95; 2.77; 2.82 score on a scale — p=0.045
N/A N=1,415 A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
Chronic Heart Failure (CHF)
Primary: Number of Clinically Stable Patients Whose Therapy Regimen Adheres to ESC Guideline Recommendations for Drug Types (Level 1) and Drug Type and Dose (Level 2) at Visit 1…
Phase 4 N=174 Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period
Complication, Postoperative
Primary: Complications, Post-anesthesia Care Unit (PACU) — 51; 58 Participants — p=0.213
N/A N=48 Somatic Mindfulness Training for a Healthy Workforce: Student Pilot Sample
Occupational-based Secondary Trauma
Primary: Secondary Traumatic Stress Scale — 35.23 units on a scale
Phase 2 N=20 A Pilot Study of Bevacizumab for Neoplastic Meningitis
Neoplastic Meningitis
Primary: Cerebrospinal Fluid (CSF) Response Rate: Percentage of Participants Positive for Tumor Cells — 93 percentage of participants
Phase 3 N=84 Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
Neuromyelitis Optica (NMO) · NMO Spectrum Disorder (NMOSD)
Primary: Time to First Protocol-Defined Relapse (TFR) in the Double-Blind Period — 120.6; NA weeks — p=0.0184
Phase 4 N=390 Tenoten® in the Treatment of Somatoform, Stress-related and Other Neurotic Disorders
Anxiety
Primary: Change From Baseline in the Mean HAM-A Score at 12 Weeks of Treatment: 1. Group 1 (Tenoten®, 4 Tablets a Day); 2. Group 3 (Tenoten®, 8 Tablets a Day). — 18.81; 18.38…
Phase 4 N=58 Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour
Contour
Primary: Percentage of Participants Who Showed ≥ 1-point Jawline Improvement From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS), as Assessed by the…
Phase 4 N=44 Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism
Metabolic Syndrome
Primary: Insulin Secretion — 293.1; 234.7; 330.8; 300.4 uU/mL*10min
Phase 1 N=104 A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: DLT Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 6; 4 Participants
N/A N=293 Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee
Osteoarthritis of the Knee
Primary: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Screening 1 by…